Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study

(2015) A. E. Nordenskjold et al.   ANNALS OF ONCOLOGY

Factors Affecting Sentinel Lymph Node Identification Rate After Neoadjuvant Chemotherapy for Breast Cancer Patients Enrolled in ACOSOG Z1071 (Alliance)

(2015) Judy C. Boughey et al.   ANNALS OF SURGERY

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

(2015) Olivia Pagani et al.   BREAST

Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer

(2015) C. S. Milagre et al.   CANCER RESEARCH

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)

(2015) Andrew Tutt et al.   CANCER RESEARCH

Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer

(2015) Rita Nanda et al.   CANCER RESEARCH

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

(2015) A. DeMichele et al.   CLINICAL CANCER RESEARCH

Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors

(2015) L. Eckhoff et al.   EUROPEAN JOURNAL OF CANCER

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

(2015) Melinda L. Telli et al.   JOURNAL OF CLINICAL ONCOLOGY

PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer

(2015) Ian J. Majewski et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience

(2015) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study

(2015) Jean-Francois Boileau et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

(2015) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score

(2015) Ivana Sestak et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

(2015) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

An international study to increase concordance in Ki67 scoring

(2015) Mei-Yin C Polley et al.   MODERN PATHOLOGY

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

(2015) Sara M. Tolaney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

(2015) Prudence A. Francis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atypical Hyperplasia of the Breast — Risk Assessment and Management Options

(2015) Lynn C. Hartmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

(2015) Halle C.F. Moore et al.   NEW ENGLAND JOURNAL OF MEDICINE

CT-planned internal mammary node radiotherapy in the DBCG-IMN study: Benefit versus potentially harmful effects

(2014) Lise B. J. Thorsen et al.   ACTA ONCOLOGICA

High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial

(2014) G. Viale et al.   ANNALS OF ONCOLOGY

Ki67 in breast cancer: a useful prognostic marker?

(2014) A. Caldarella et al.   ANNALS OF ONCOLOGY

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

(2014) S. Loi et al.   ANNALS OF ONCOLOGY

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

(2014) M. Gnant et al.   ANNALS OF ONCOLOGY

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

(2014) J.- C. Soria et al.   ANNALS OF ONCOLOGY

Which threshold for ER positivity? a retrospective study based on 9639 patients

(2014) M. Yi et al.   ANNALS OF ONCOLOGY

Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

(2014) Beyhan Ataseven et al.   ANNALS OF SURGICAL ONCOLOGY

Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

(2014) Torsten Nielsen et al.   BMC CANCER

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

(2014) Qin Feng et al.   CELL RESEARCH

Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study

(2014) F. Klauschen et al.   CLINICAL CANCER RESEARCH

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

(2014) A. Prat et al.   CLINICAL CANCER RESEARCH

Use of and Mortality After Bilateral Mastectomy Compared With Other Surgical Treatments for Breast Cancer in California, 1998-2011

(2014) Allison W. Kurian et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor–Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group

(2014) Amye J. Tevaarwerk et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

(2014) Evandro de Azambuja et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

PIK3CAMutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer

(2014) Sibylle Loibl et al.   JOURNAL OF CLINICAL ONCOLOGY

Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer

(2014) Meena S. Moran et al.   JOURNAL OF CLINICAL ONCOLOGY

Margins in breast conservation: A clinician's perspective and what the literature tells us

(2014) Nehmat Houssami et al.   JOURNAL OF SURGICAL ONCOLOGY

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

(2014) Evandro de Azambuja et al.   LANCET ONCOLOGY

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial

(2014) Mila Donker et al.   LANCET ONCOLOGY

Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy

(2014) Soley Bayraktar et al.   MEDICAL ONCOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

(2014) Olivia Pagani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

(2013) C. Denkert et al.   ANNALS OF ONCOLOGY

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

(2013) A. Schneeweiss et al.   ANNALS OF ONCOLOGY

Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy

(2013) Lynn T. Dengel et al.   ANNALS OF SURGICAL ONCOLOGY

High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer

(2013) Carmen Criscitiello et al.   BREAST

Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research

(2013) N. Bouganim et al.   BREAST CANCER RESEARCH AND TREATMENT

Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002

(2013) Katharine Yao et al.   BREAST CANCER RESEARCH AND TREATMENT

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

(2013) G Allevi et al.   BRITISH JOURNAL OF CANCER

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

(2013) P Dubsky et al.   BRITISH JOURNAL OF CANCER

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

(2013) H. Masuda et al.   CLINICAL CANCER RESEARCH

Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

(2013) Y. Zhang et al.   CLINICAL CANCER RESEARCH

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

(2013) F. Andre et al.   CLINICAL CANCER RESEARCH

Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From a Herceptin Adjuvant Trial

(2013) Ann H. Partridge et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

(2013) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

(2013) Kelly-Anne Phillips et al.   JOURNAL OF CLINICAL ONCOLOGY

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

(2013) Ivana Sestak et al.   JNCI-Journal of the National Cancer Institute

An International Ki67 Reproducibility Study

(2013) Mei-Yin C. Polley et al.   JNCI-Journal of the National Cancer Institute

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials

(2013) Joanne S Haviland et al.   LANCET ONCOLOGY

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

(2013) Thorsten Kuehn et al.   LANCET ONCOLOGY

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

(2013) A. Prat et al.   ONCOLOGIST

ASCO's Approach to a Learning Health Care System in Oncology

(2013) George W. Sledge et al.   Journal of Oncology Practice

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

(2012) W. Eiermann et al.   ANNALS OF ONCOLOGY

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

(2012) Roy RL Bastien et al.   BMC Medical Genomics

Increasing rates of contralateral prophylactic mastectomy – A trend made in USA?

(2012) U. Güth et al.   EJSO

Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101

(2012) Lawrence N. Shulman et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer

(2012) Aleix Prat et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

(2011) G. Viale et al.   ANNALS OF ONCOLOGY

The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer

(2011) Steven A. Narod   BREAST CANCER RESEARCH AND TREATMENT

Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis

(2011) Armando E. Giuliano   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer

(2011) Lucia Del Mastro et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Effect of Luteinizing Hormone–Releasing Hormone Agonist on Ovarian Function After Modern Adjuvant Breast Cancer Chemotherapy: The GBG 37 ZORO Study

(2011) Bernd Gerber et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer

(2010) T. O. Nielsen et al.   CLINICAL CANCER RESEARCH

Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer

(2010) Timothy J. Whelan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?

(2008) M. M. Regan et al.   ANNALS OF ONCOLOGY